Combination of a leucine source and an omega-3 unsaturated fatty acid source for use in the treatment of hypercalcaemia
AssigneeN.V. Nutricia
InventorsKlaske Van Norren, Joyce Faber, Adrianus Lambertus Bertholdus Van Helvoort, Robert Johan Joseph Hageman
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.
Claims31
A method for the therapeutic treatment of hypercalcaemia in an individual, comprising administering to the individual a composition comprising a leucine source and an ω-3 unsaturated fatty acid source providing an ω-3 polyunsaturated fatty acid selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid, wherein the individual is a subject suffering from a cancer, and wherein the composition further includes at least one indigestible oligosaccharide.
A method for the therapeutic treatment of hypercalcaemia in an individual, comprising administering to the individual a composition comprising a leucine source and an ω-3 unsaturated fatty acid source providing an ω-3 polyunsaturated fatty acid selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid, wherein the individual is a subject suffering from a cancer and, wherein the composition comprises at least 15 g/kg free leucine, based on total weight of proteinaceous matter, fat, carbohydrates plus dietary fibres, of the composition.
A method for the prophylactic or therapeutic treatment of hypercalcaemia in an individual comprising administering to the individual a nutritional composition comprising proteinaceous matter, a lipid, and a digestible carbohydrate, wherein
- a) the proteinaceous matter content provides 18 to 50 en % of the total composition;
- the proteinaceous matter providing a leucine source providing at least 15 g/kg leucine, based on total weight of proteinaceous matter, fat, carbohydrates, plus fibers of the composition, a first part of the leucine being in a free form, a second part provided by whey protein,
- b) the lipid content provides 10 to 50 en % of the total composition;
- the lipid comprising and an ω-3 polyunsaturated fatty acid source providing eicosapentaenoic acid and docosahexaenoic acid, wherein the ω-3 polyunsaturated fatty acid content is at least 15 g/kg,
- c) the digestible carbohydrate content provides 20 to 70 en %, of the total composition.
- d) an indigestible carbohydrate selected from the group of galactooligosaccharides (GOS) and fructooligosaccharides (FOS), the composition having a glycemic index of less than 55.
Dependencies are inferred from the claim text.